* Dapirolizumab pegol (DZP) showed efficacy across multiple clinical endpoints in the PHOENYCS GO study, including fatigue and measures of disease activity * DZP showed consistent improvements in fatigue, a common and debilitating symptom of systemic lupus erythematosus (SLE) * At Week 48, more individuals receiving DZP experienced no or low disease activity compared to standard of care with differences observed as early as Week 12 BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE)...
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Gladman
Contact Gladman, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack